About Medtronic The submissions included a 510(k) application for its MiniMed™ 780G pump as an alternate controller enabled (ACE) insulin pump and a separate 510(k) application for its SmartGuard™ algorithm as an interoperable automated glycemic controller (iAGC). "We understand how meaningful these advancements are, and we're working with urgency to bring enhanced CGM options to our customers," said Que Dallara, EVP & president, Medtronic Diabetes. "This collaboration with Abbott marks an important step fo ...

Core Viewpoint - Medtronic plc is positioned as a strong investment option due to its combination of defensive traits, growth opportunities, and a solid dividend history, making it resilient in volatile markets [1][2][3]. Financial Performance - Medtronic reported a revenue of $8.29 billion in fiscal Q3 2025, with a non-GAAP EPS of $1.39, surpassing the consensus estimate of $1.36 [11]. - The company reaffirmed its full-year fiscal 2025 guidance, projecting organic revenue growth of 4.75% to 5.0% [10][12]. Dividend Information - Medtronic has a current dividend yield of 3.38%, with an annual dividend of $2.80 and a dividend increase track record of 48 years [5][6]. - The recent quarterly dividend payment was confirmed at $0.70 per share, reflecting the company's commitment to providing reliable income to investors [5]. Market Position and Stability - With a market capitalization of approximately $104.9 billion, Medtronic addresses around 70 health conditions globally, providing stability against economic shifts [2][6]. - The company has a beta of 0.79, indicating lower volatility compared to the broader market, making it attractive for risk-averse investors [7]. Innovation and Growth Potential - Medtronic's innovation pipeline includes key products like the Simplera Sync™ CGM Sensor and the BrainSense™ aDBS System, which enhance its competitiveness in high-growth segments [13][17]. - The company's Cardiovascular division is supported by strong clinical data, reinforcing its market leadership and potential for long-term growth [18][16]. Analyst Ratings and Stock Forecast - The 12-month stock price forecast for Medtronic is $96.14, indicating a potential upside of 16.08% from the current price of $82.83 [15]. - Despite a Hold rating among analysts, Medtronic is recognized for its reliable income and engagement in significant medical advancements, positioning it as a sound choice for long-term value [19].